Compare GDYN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDYN | CTMX |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 727.6M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | GDYN | CTMX |
|---|---|---|
| Price | $9.27 | $4.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $11.25 | $6.50 |
| AVG Volume (30 Days) | 943.5K | ★ 2.8M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 457.52 | 50.22 |
| EPS | 0.16 | ★ 0.24 |
| Revenue | ★ $405,955,000.00 | $113,631,000.00 |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $10.24 | N/A |
| P/E Ratio | $56.87 | ★ $18.32 |
| Revenue Growth | ★ 23.63 | N/A |
| 52 Week Low | $7.37 | $0.40 |
| 52 Week High | $25.50 | $4.62 |
| Indicator | GDYN | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 61.95 |
| Support Level | $9.07 | $3.86 |
| Resistance Level | $9.95 | $4.37 |
| Average True Range (ATR) | 0.37 | 0.26 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 16.23 | 90.71 |
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.